Program Director/Principal Investigator (Last, First, Middle):
Meyskens, Frank L.
5P30CA062203-17
BIOGRAPHICAL SKETCH
Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. DO NOT EXCEED FOUR PAGES.
NAME
POSITION TITLE
Shen, Violet
-CHOC Clinical Director, Research
-Director of Clinical Research Office at UC Irvine
Chao Family Comprehensive Cancer Center
eRA COMMONS USER NAME (credential, e.g., agency login)
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and
residency training if applicable.)
DEGREE
INSTITUTION AND LOCATION
MM/YY
FIELD OF STUDY
(if applicable)
National Taiwan University College of Medicine,
Taiwan
MD
Cornell Medical College North Shore University
Hospital, Manhasset, N.Y.
06/79
06/83
Memorial Sloan-Kettering Cancer Center and
Cornell Medical College-New York Hospital
08/86
Medicine
Pediatric residency
Fellowship in Pediatric
Hematology-Oncology
A. Personal Statement
I am a strong believer in oncology clinical research. As a pediatric oncologist for 25 years, I witness
tremendous advance in cancer research translating into significant improvement of survival and the quality of life
in children with cancer. As a cancer survivor myself, I truly appreciate the advent of cancer research which
saved my life. I did laboratory research in cancer genetics during my fellowship at Memorial Sloan-Kettering
Cancer Center and assistant professor years at University of California Irvine. Later when I became the principle
investigator of Children’s Oncology Group (COG) at Children’s Hospital of Orange County (CHOC) in 1998, I
strived to build a strong clinical research team by cultivating the high awareness and appreciation of the clinical
research within the institute. We opened over hundreds of studies and screened every new and recurrent cancer
patient for eligibility of research studies. With high patient accrual rate, successful audits and the overall high
quality of the research program, CHOC was selected as one of only 21 institutions in the North America to
participate in the COG Phase One Consortium in 2006. We have since opened 30 COG phase one studies at
CHOC and became one of the top enrolling institutions within the consortium. We have successfully renewed
our membership of the Phase One Consortium in 2011.
I have also collaborated with pharmaceutical companies to bring the cutting edge therapeutic and supportive
care studies to CHOC. I have been the local principle investigator for the following studies: Sequential high dose
thiotepa for CNS tumor (investigator-initiated), Clofarabine single agent and combination for refractory acute
leukemia, anti-IGF1R antibody for recurrent sarcoma, Erlotinib vs. Etoposide for recurrent ependymoma,
L-MTP-PE for recurrent Osteosarcoma. I conducted supportive care studies of hematopoietic growth factors,
antiemetics, analgesics, thrombolytic therapy and rasburicase for hyperuricemia. Working with industry
sponsored studies gave me different perspectives in study design, patient accrual strategies, data management
and manuscript preparation. I have reviewed many concept proposals and the study design of clinical trials as
the principle investigator and the member of COG study committees. Having been involved with many clinical
trials over the years gives me a good sense of feasibility and the merit of the study.
Because of these experiences, I was offered an appointment as Director of Clinical Research Office (CRO) at
the UC Irvine Chao Family Comprehensive Cancer (CFCCC) starting October, 2011. In this position, I serve as
a liaison between center investigators, center’s research administration, various university entities and the
community. My focus will be to enhance translational oncology research at UCI and to support HDII protocol
development through continuous evaluation of cancer center’s protocol portfolio and health need of the
community. I will participate in Clinical Research Advisory Council (CRAC) and Clinical Trials Protocol Review
and Monitoring Committee (CTPRMC) to evaluate the scientific merit and accrual of clinical research conducted
PHS 398/2590 (Rev. 06/09)
Page
Biographical Sketch Format Page
Program Director/Principal Investigator (Last, First, Middle):
Meyskens, Frank L.
5P30CA062203-17
at the Cancer Center. I will work with CRO staffs and the Data Safety Monitoring Board (DSMB) to ensure timely
reporting of adverse events, safety of protocol participants and the integrity and comprehensiveness of the
reported data.
Clinical Cancer research is at a very exciting time as many new agents targeting different molecular
pathways are in various phases of development. We will be able to achieve personalized medicine in the
treatment of many cancers by applying genomics and biomarkers to select best combination of target therapies.
I will continue to promote oncology clinical research at both Children’s Hospital of Orange County and UC Irvine
CFCCC, two premier institutions in Orange County, CA.
B. Positions and Honors
Positions
1996-2002
19961998-2001
199820012000-2010
200620092011Honors
1986
1987
1988
1989
2005-2010
2011
Chairman, CHOC Cancer Committee
Chairman, Oncology Section of Medical Staff
Director, Oncology Program at CHOC
COG Principal Investigator for CHOC
Clinical Research Director at CHOC
Investigator of Pediatric Cancer Research Foundation
Principle Investigator of COG phase I consortium at CHOC
Director of CHOC Cancer Institute Neuro-Oncology Program
Director of Clinical Research Office at UC Irvine Chao Family Comprehensive Cancer Center
Upjohn Travel Award for the abstract presented in 1986 American Association for Cancer
Research annual meeting
Faculty Research Grant, UC Irvine
Faculty Research Grant, UC Irvine
Faculty Developmental Award, UC Irvine
Selected as one of the Top Doctors of Orange County by OCMA
Invited speaker to Grand Round of Department of Pediatrics, National Taiwan University, April 11
Memberships
American Society of Pediatric Hematology-Oncology
American Society of Clinical Oncology
Children Oncology Group
Society of Neuro-Oncology
Member of COG Brain Tumor Study Committees (9941, 99702, 99703, ACNS02B1)
Vice chair of CCG 99702 study
PI auditor for COG (2006-2008)
C. Selected Peer-reviewed Publications
1. Shen W.V., Aldrich T, Perez G., Franza B.R., Furth M. Expression of normal and mutant ras protein in human
leukemia. Oncogene 2:157-165(1987). PMID: 3325880
2. Meyers MB, Shen V, Spengler BA et al: Increased epidermal growth factor receptor in multidrug-resistant
human neuroblastoma cells. Journal of Cellular Biochemistry 38:87-97 (1988). PMID: 246460
3. Shen WV, Walter B, Young R, Choi B., Smith M, Katz J: Molecular analysis of a myxoid chondrosarcoma
showing rearrangement in chromosome 10 and 22. Cancer Genetics and Cytogenetics 45:207-215 (1990).
PMID: 1969328
4. Shen, W.V., Chapparro M., Young R., Bernstein R.: Absence of isochromosome 12p in a pineal region
malignant germ cell tumor. Cancer Genetics and Cytogenetics 50:153-160 (1990). PMID: 2253184
PHS 398/2590 (Rev. 06/09)
Page
Biographical Sketch Format Page
Program Director/Principal Investigator (Last, First, Middle):
Meyskens, Frank L.
5P30CA062203-17
5. Shen V, Woodbury, Killen R, Van de Ven C, Sender L, Cairo MS: Collection and use of peripheral blood stem
cells in young children with refractory solid tumors. Bone Marrow Transplantation 19:197-204. (1997). PMID:
9028545
6. Bracho F, Krailo M, Shen V, Bergeron S,, Liu-Mares W, Blazer B, van der Ven, C, Secola R, Ames M,
Reaman G, Cairo MS: A phase I clinical, pharmacologic and biological trial of interleukin-6 (IL-6) following
Ifosfamide, Carboplatin, Etoposide (ICE) in children with recurrent/refractory solid tumors: Enhanced
hematological responses but a high incidence of grade III/IV toxicities. Clinical Cancer Research
7:58-67,2001. PMID: 11205919
7. Cairo MS, Shen V, Krailo M, Bauer M, Miser J, Blatt J, Sato J, Liu W, Reaman G: Prospective randomized
trial between two doses of granulocyte colony-stimulating factor after Ifosfamide, Carboplatin, and Etoposide
(ICE) in Children with Recurrent of Refractory Solid Tumors: A Children’s Cancer Group Report. J Pediatr
Hematol Oncol 23:30-38,2001. PMID: 11196267
8. Goldman SC, Bracho F, Davenport V, Slack R, Areman E, Shen V, Lenarsky C, Weinthal J, Hughes R, Cairo
MS: A feasibility study of Interleukin-11 and G-CSF following myelosuppressive chemotherapy to mobilize
peripheral blood stem cells (CD34+) from heavily pretreated patients. J Pediatr Hematol Oncol 23(5):300-5,
2001. PMID: 11464987
9. Hong R, Shen V, Rooney C, Hughes D, Smith C, Comoli P, Zhang L: Correction of DiGeorge Anomaly with
EBV-induced lymphoma by transplantation of organ cultured thymus and Epstein-Barr specific T
lymphocytes. Clinical Immunology 98:54-61,2001. PMID: 11141327
10. Jennings M, Sposto R, Boyett J, Vezina G, Pollack I, Shen V etc: Preradiation chemotherapy in primary high
risk brain stem tumors: CCG-9941, a phase II study of the Childrens Cancer Group. J Clin Oncol
20:3431-3427, 2002. PMID: 12177103
11. Shen V, Li X, Murdock M, Resnansky L, McCluskey E, Semba C: Recombinant tissue plasminogen activator
(Alteplase) for restoration of function to occluded central venous catheters in pediatric patients. J Pediatr
Hematol Oncol 25: 38-45, 2003. PMID: 12544772
12. Jeha S, Kantarjian H, Irwin D, Shen V, Shenoy S, Blaney S, Camitta B, Pui CH. Efficacy and safety of
rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated
hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial.
Leukemia. 19(1):34-8, 2005. PMID: 15510203
13. S Jeha, PS. Gaynon, B Razzouk, J Franklin, R Kadota, V Shen, L Luchtman-Jones, M Rytting, L Bomgaars,
S Rheingold, K Ritchey, E Albano, RJ. Arceci, S Goldman, T Griffin, A Altman, B Gordon, Ll Steinherz, S
Weitman, P Steinherz. Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute
Lymphoblastic Leukemia. J Clin Oncol, Vol 24, No 12 , pp. 1917-1923,2006. PMID: 16622268
14. N Hijiya, P Gaynon, E Barry, L Silverman, B Thomson, R Chu, T Cooper, R Kadota, M Rytting, P Steinherz,V
Shen, S Jeha, R Abichandan and WL Carroll: A multi-center phase I study of clofarabine, etoposide and
cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia
23, 2259–2264,2009. PMID: 19741725
D. Research Support
Ongoing Research Support
5P30CA062203-16
Meyskens (PI)
02/01/09-01/31/14
NIH/NCI
University of California Irvine Cancer Center Support Grant Infrastructure and Research award to support cancer
research at UC Irvine and beyond.
Role: Director CRO research
U01 CA97452-10
Susan Blaney (PI)
9/16/11-7/31/12
Children’s Oncology Group Phase 1/Pilot consortium Grant subcontract No.021368
Role: institutional PI
ADVL0813
NCI
Clinical Trial
PHS 398/2590 (Rev. 06/09)
Shen (PI)
06/01/09-05/31/12
Page
Biographical Sketch Format Page
Program Director/Principal Investigator (Last, First, Middle):
Meyskens, Frank L.
5P30CA062203-17
Phase I/Pilot Consortium to identify and develop effective new agents for children and adolescents with cancer
(prime award# U01CA097452, PI Susan Blaney).
Role: Co:PI
ADVL0911
Shen (PI)
06/01/09-05/31/12
NCI
Clinical Trial
Phase I/Pilot Consortium is to identify and develop effective new agents for children and adolescents with cancer
through rational and efficient clinical and laboratory research (prime award# U10CA097452-07S1, PI Susan
Blaney)
ANBL0931
Shen (PI)
06/01/09-05/31/12
NCI
Childhood cancers (Prime award# U10CA098543, PI Peter Adamson)
Role: Co:PI
Completed Research
U10 CA98543-06
NCI
NCCF subcontract
Role: Co:PI
03/1/08-02/28/11
U01 CA097452-06
NCI
COG Phase One Consortium Grant
Role: Co PI
PHS 398/2590 (Rev. 06/09)
08/01/07-07/31/11
Page
Biographical Sketch Format Page